Safety of snake antivenom immunoglobulins: Efficacy of viral inactivation in a complete downstream process

Biotechnology Progress

Volumn 29, Issue 4, 2013, Pages 972-979

  Caricati, C P ^a   Oliveira Nascimento, L ^b   Yoshida, J T ^b   Stephano, M A ^b   Caricati, A T P ^a   Raw, I ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antivenom; Immunoglobulin; Phenol; Viral safety

Indexed keywords

ANTIVENOM; CAPRYLIC ACID; DOWNSTREAM PROCESS; IMMUNOGLOBULIN; PHENOL TREATMENT; SAFE PRODUCTS; VIRAL INACTIVATION; VIRAL REDUCTION;

PHENOLS;

VIRUSES;

ADENOVIRIDAE; EQUIDAE; ROTAVIRUS;

IMMUNOGLOBULIN; PHENOL; PHENOL DERIVATIVE; SNAKE VENOM; VENOM ANTISERUM;

ANIMAL; ANTIVENOM; ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG CONTAMINATION; DRUG EFFECT; HEAT; HORSE; IMMUNOLOGY; ISOLATION AND PURIFICATION; SAFETY; SNAKE; VIRAL SAFETY; VIRUS; VIRUS INACTIVATION; WORLD HEALTH ORGANIZATION;

ANTIVENOM; IMMUNOGLOBULIN; PHENOL; VIRAL SAFETY;

ANIMALS; ANTIVENINS; DRUG CONTAMINATION; HORSES; HOT TEMPERATURE; PHENOLS; SAFETY; SNAKE VENOMS; SNAKES; VIRUS INACTIVATION; VIRUSES; WORLD HEALTH ORGANIZATION;

EID: 84881612634     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.1758     Document Type: Article

References (56)

1. Kasturiratne A, Wickremasinghe AR, De Silva N, Gunawardena NK, Pathmeswaran A, Premaratna R, Savioli L, Laloo DG, de Silva HJ. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med. 2008;5:e218.
2. Espino Solis GP, Riaño-Umbarila L, Becerril B, Possani LD. Antidotes against venomous animals: state of the art and prospectives. J Proteomics. 2009;72:183-199.
3. WHO. WHO | WHO model lists of essential medicines. WHO. Available at: http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed July 11, 2012.
4. Razvi S, Schneider L, Jonas MM, Cunningham-Rundles C. Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. Clin Immunol. 2001;101:284-288.
5. Quinti I, Pierdominici M, Marziali M, Giovannetti A, Donnanno S, Chapel H, Bjorkander J, Aiuti F. European surveillance of immunoglobulin safety-results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries. Clin Immunol. 2002;104:231-236.
6. Carbone J, Sarmiento E, Fernandez Cruz E. Overwhelming course of HCV disease in patients with hypogammaglobulinemia associated with cellular immunity deficiency. Rev Gastroenterol Peru. 2005;25:19-22.
7. Gutierrez JM, Leon G, Burnouf T. Antivenoms for the treatment of snakebite envenomings: the road ahead. Biologicals. 2011;39:129-142.
8. Burnouf T, Griffiths E, Padilla A, Seddik S, Stephano MA, Gutierrez JM. Assessment of the viral safety of antivenoms fractionated from equine plasma. Biologicals. 2004;32:115-128.
9. Theakston RDG, Warrell DA, Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon. 2003;41:541-557.
10. Rossi F, Legras JF. Viral safety: european and french directives. Ann Med Interne (Paris). 2000;151(Suppl 1):1S55-1S61.
11. Burnouf T, Terpstra F, Habib G, Seddik S. Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms. Biologicals. 2007;35:329-334.
12. Solano S, Segura Á, León G, Gutiérrez J-M, Burnouf T. Low pH formulation of whole IgG antivenom: impact on quality, safety, neutralizing potency and viral inactivation. Biologicals. 2012;40:129-133.
13. Petschow BW, Talbott RD. Reduction in virus-neutralizing activity of a bovine colostrum immunoglobulin concentrate by gastric acid and digestive enzymes. J Pediatr Gastroenterol Nutr. 1994;19:228-235.
14. Hamilton M, Russo R, Thurston R. Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays. Environ Sci Technol. 1977;11:714-719.
15. Engvall E. Enzyme immunoassay ELISA and EMIT. Meth Enzymol. 1980;70:419-439.
16. Pope CG. The action of proteolytic enzymes on the antitoxins and proteins in immune sera: I. True digestion of the proteins. Br J Exp Pathol. 1939;20:132-149.
17. Pope CG. The action of proteolytic enzymes on the antitoxins and proteins in immune sera: II. Heat denaturation after partial enzyme action. Br J Exp Pathol. 1939;20:201-212.
18. Pope CG, Stevens MF. The action of proteolytic enzymes on the antitoxins and proteins in immune sera. Br J Exp Pathol. 1951;32:314-324.
19. Larzul D. Viral validation design of a manufacturing process. Dev Biol Stand. 1999;99:139-150.
20. WHO. WHO | WHO guidelines for the production, control and regulation of snake antivenom immunoglobulins. WHO. Available at: http://www.who.int/bloodproducts/snake_antivenoms/snakeantivenomguide/en/. Accessed July 11, 2012.
21. Guideline, ICH Harmonized Tripartite. Q5A: quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Fed Reg. 1998; 63:51074.
22. Nagai M, Ito T, Sugita S, Genno A, Takeuchi k, Ozawa T, Sakoda Y, Nishimori T, Takamura K, Akashi H. Genomic and serological diversity of bovine viral diarrhea virus in Japan. Arch Virol. 2001;146:685-696.
23. Wellenberg GJ, Mars MH, Van Oirschot JT. Antibodies against bovine herpesvirus (BHV) 5 may be differentiated from antibodies against BHV1 in a BHV1 glycoprotein E blocking ELISA. Vet Microbiol. 2001;78:79-84.
24. Guidry AJ, O Brien CN. A method for measuring specific antibodies in bovine lacteal secretions during the nonlactating period. J Dairy Sci. 1996;79:846-850.
25. Campos ACMR, Freitas MCWD, Yamaguchi IK, Marcelino JR, Dias da Silva W. A sensitive and specific immunoassay for the measurement of the antibodies present in horse antivenoms endowed with the capacity to block the phospholipase a2-dependent hemolysis induced by snake venoms. J Venom Anim Toxins. 1996;2:106-120.
26. Nowak T, Gregersen J-P, Klockmann U, Cummins LB, Hilfenhaus J. Virus safety of human immunoglobulins: efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure. J Med Virol. 1992;36:209-216.
27. Rojas G, Vargas M, Robles A, Gutiérrez JM. Turbidity of hyperimmune equine antivenom: the role of phenol and serum lipoproteins. Toxicon. 1993;31:61-66.
28. Buchacher A, Iberer G. Purification of intravenous immunoglobulin G from human plasma-aspects of yield and virus safety. Biotechnol J. 2006;1:148-163.
29. Biescas H, Gensana M, Fernández J, Ristol P, Massot M, Watson E, Vericat, F. Characterization and viral safety validation study of a pasteurized therapeutic concentrate of antithrombin III obtained through affinity chromatography. Haematologica. 1998;83:305-311.
30. CPMP. Note for guidance on production and quality control of animal immunoglobulins and immunsera for human use. European Agency for the Evaluation of Medicinal Products (EMEA). Avaiable at: http://www.who.int/bloodproducts/publications/EMEA-animal%20sera.pdf. Accessed July 30, 2012.
31. WHO. WHO | Technical report, Series No. 924, 2004, annex 4: guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. WHO. Available at: http://www.who.int/bloodproducts/publications/WHO_TRS_924_A4.pdf. Accessed July 11, 2012.
32. Henzler H-J, Kaiser K. Avoiding viral contamination in biotechnological and pharmaceutical processes. Nat Biotechnol. 1998;16:1077-1079.
33. Kempf C, Jentsch P, Poirier B, Barré-Sinoussi F, Morgenthaler JJ, Morell A, Germann D. Virus inactivation during production of intravenous immunoglobulin. Transfusion. 1991;31:423-427.
34. Pratelli A. Canine coronavirus inactivation with physical and chemical agents. Vet J. 2008;177:71-79.
35. Lundblad JL, Seng RL. Inactivation of lipid-enveloped viruses in proteins by caprylate. Vox Sang. 1991;60:75-81.
36. Caballero S, Nieto S, Gajardo R, Jorquera JI. Viral safety characteristics of Flebogamma® DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin. Biologicals. 2010;38:486-493.
37. Mpandi M, Schmutz P, Legrand E, Duc R, Geinoz J, Henzelin Nkubana C, Giorgia S, Clerc O, Genoud D, Weber T. Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins. Biologicals. 2007;35:335-341.
38. Korneyeva M, Hotta J, Lebing W, Rosenthal RS, Franks L, Petteway SR Jr. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates. Biologicals. 2002;30:153-162.
39. Morais V, Massaldi H. Effect of pepsin digestion on the antivenom activity of equine immunoglobulins. Toxicon. 2005;46:876-882.
40. Uemura Y, Yang YH, Heldebrant CM, Takechi K, Yokoyama K. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin. Vox Sang. 1994;67:246-254.
41. Maillard J-Y. Antimicrobial biocides in the healthcare environment: efficacy, usage, policies, and perceived problems. Ther Clin Risk Manag. 2005;1:307-320.
42. Moore MA. Inactivation of enveloped and non-enveloped viruses on seeded human tissues by gamma irradiation. Cell Tissue Bank. 2012;13:401-407.
43. Armstrong JA, Froelich EJ. Inactivation of viruses by benzalkonium chloride. Appl Microbiol. 1964;12:132-137.
44. Nemo GJ, Ernest CC. Effect of visible light on canine distemper virus1. J Bacteriol. 1966;91:798-802.
45. Weiss C, Clark HF. Rapid inactivation of rotaviruses by exposure to acid buffer or acidic gastric juice. J Gen Virol. 1985;66(Pt 12):2725-2730.
46. Yamamoto T, Maruysk RG. Morphological studies of a canine adenovirus. J. Gen. Virol. 1968;2:191-194.
47. Petr G, Jiran E. The effect of temperature on the hemagglutinin activity of the canine adenovirus (infectious canine hepatitis virus). Zentralbl Veterinarmed. 1970;17B:569-581.
48. Yamamoto T. The effect of ion concentration and pH on the thermal stability of a canine adenovirus. Can J Microbiol. 1967;13:1139-1149.
49. Terpstra FG, Parkkinen J, Tölö H, Koenderman AHL, Ter Hart HGJ, von Bonsdorff L, Torma E, van Engelenburg, FAC. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product. Vox Sang. 2006;90:21-32.
50. Roberts PL, Hart H. Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates. Biologicals. 2000;28:185-188.
51. Valdes R, Ibarra N, Ruibal I, Beldarrain A, Noa E, Herrera N, Alemen R, Padilla S, Garcia J, Perez M, Moralez R, Chong E, Reyes B, Quinones Y, Agraz A, Herrera L. Chromatographic removal combined with heat, acid and chaotropic inactivation of four model viruses. J.Biotechnol. 2002;96:251-258.
52. Klein M, Deforest A. Chemical inactivation of viruses. Fed Proc. 1965;24:319.
53. Buckwold VE, Beer BE, Donis RO. Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents. Antiviral Res. 2003;60:1-15.
54. van Engelenburg FAC, Terpstra FG, Schuitemaker H, Moorer WR. The virucidal spectrum of a high concentration alcohol mixture. J Hosp Infect. 2002;51:121-125.
55. Morgenthaler J-J. Securing viral safety for plasma derivatives. Transfus Med Rev. 2001;15:224-233.
56. Shen DT, Crawford TB, Gorham JR, McGuire TC. Inactivation of equine infectious anemia virus by chemical disinfectants. Am J Vet Res. 1977;38:1217-1219.